-+ 0.00%
-+ 0.00%
-+ 0.00%

The FDA Has Approved Shanghai Henlius Biotech And Organon's Partnered Biologics License Application For Poherdy, An Interchangeable Biosimilar To Perjeta (Pertuzumab), For All Indications Of The Reference Product

Benzinga·11/17/2025 10:32:16
Listen to the news

POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.